Rhinomed Past Earnings Performance
Past criteria checks 0/6
Rhinomed's earnings have been declining at an average annual rate of -8.2%, while the Pharmaceuticals industry saw earnings growing at 31.2% annually. Revenues have been growing at an average rate of 27.6% per year.
Key information
-8.2%
Earnings growth rate
12.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 31.2% |
| Revenue growth rate | 27.6% |
| Return on equity | n/a |
| Net Margin | -135.5% |
| Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
Recent updates
Rhinomed Limited's (ASX:RNO) CEO Will Probably Find It Hard To See A Huge Raise This Year
Nov 10
Is Rhinomed (ASX:RNO) Using Too Much Debt?
Mar 03Rhinomed (ASX:RNO) Is In A Strong Position To Grow Its Business
Mar 01Here's Why We're Not Too Worried About Rhinomed's (ASX:RNO) Cash Burn Situation
Jul 09Here's Why We're Watching Rhinomed's (ASX:RNO) Cash Burn Situation
Mar 01Key Things To Understand About Rhinomed's (ASX:RNO) CEO Pay Cheque
Jan 25How Many Rhinomed Limited (ASX:RNO) Shares Did Insiders Buy, In The Last Year?
Dec 20Revenue & Expenses BreakdownBeta
How Rhinomed makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 8 | -11 | 12 | 1 |
| 31 Mar 23 | 9 | -9 | 11 | 1 |
| 31 Dec 22 | 9 | -7 | 11 | 2 |
| 30 Sep 22 | 10 | -6 | 10 | 2 |
| 30 Jun 22 | 10 | -5 | 10 | 2 |
| 31 Mar 22 | 8 | -6 | 10 | 1 |
| 31 Dec 21 | 6 | -6 | 9 | 1 |
| 30 Sep 21 | 5 | -8 | 10 | 1 |
| 30 Jun 21 | 4 | -9 | 10 | 1 |
| 31 Mar 21 | 5 | -8 | 10 | 1 |
| 31 Dec 20 | 5 | -7 | 9 | 0 |
| 30 Sep 20 | 5 | -7 | 9 | 0 |
| 30 Jun 20 | 4 | -7 | 9 | 0 |
| 31 Mar 20 | 4 | -8 | 9 | 0 |
| 31 Dec 19 | 4 | -8 | 9 | 0 |
| 30 Sep 19 | 4 | -7 | 8 | 0 |
| 30 Jun 19 | 3 | -6 | 7 | 0 |
| 31 Mar 19 | 3 | -5 | 6 | 0 |
| 31 Dec 18 | 3 | -5 | 6 | 0 |
| 30 Sep 18 | 3 | -5 | 5 | 0 |
| 30 Jun 18 | 2 | -4 | 5 | 0 |
| 31 Mar 18 | 2 | -4 | 5 | 0 |
| 31 Dec 17 | 1 | -5 | 5 | 0 |
| 30 Sep 17 | 2 | -5 | 5 | 0 |
| 30 Jun 17 | 2 | -4 | 5 | 0 |
| 31 Mar 17 | 2 | -5 | 5 | 0 |
| 31 Dec 16 | 2 | -5 | 5 | 0 |
| 30 Sep 16 | 1 | -5 | 5 | 0 |
| 30 Jun 16 | 1 | -6 | 6 | 0 |
| 31 Mar 16 | 1 | -6 | 5 | 0 |
| 31 Dec 15 | 1 | -6 | 5 | 1 |
| 30 Sep 15 | 1 | -6 | 5 | 1 |
| 30 Jun 15 | 0 | -5 | 4 | 1 |
| 31 Mar 15 | 0 | -5 | 3 | 1 |
| 31 Dec 14 | 0 | -5 | 2 | 0 |
| 30 Sep 14 | 0 | -4 | 1 | 0 |
| 30 Jun 14 | 0 | -4 | 1 | 0 |
| 31 Mar 14 | 0 | -4 | 0 | 0 |
| 31 Dec 13 | 0 | -4 | 2 | 0 |
| 30 Sep 13 | 0 | -9 | 2 | 0 |
| 30 Jun 13 | 0 | -15 | 2 | 0 |
Quality Earnings: RNO is currently unprofitable.
Growing Profit Margin: RNO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: RNO is unprofitable, and losses have increased over the past 5 years at a rate of 8.2% per year.
Accelerating Growth: Unable to compare RNO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RNO is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-10%).
Return on Equity
High ROE: RNO's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.